Guangzhou Rare Disease Gene Therapy Alliance


Guangzhou Rare Disease Gene Therapy Alliance, also known as the "Guangzhou Rare Disease Gene Therapy Industry-University-Research Collaborative Innovation Alliance", is led by Tsinghua Pearl River Institute of Rare Diseases, and consists of several universities, research institutions, hospitals, innovative pharmaceutical companies, CDMO enterprises, investment institutions, and social organizations in the province and the country that are involved in rare disease gene therapy research. It was officially registered with the Guangzhou Science and Technology Bureau on October 13, 2021, and held its inaugural meeting and the first Guangdong-Hong Kong-Macau Greater Bay Area Rare Disease Gene Therapy Summit Forum on November 12, 2021.

This alliance will abide by national laws and regulations, adhere to social morality, advocate for public awareness and care for rare disease communities, and leverage the strengths of industry, academia, research, and medicine. It aims to break down information barriers, integrate clinical and research resources for rare diseases, and use big-data technologies such as bioinformatics and artificial intelligence to develop systematic solutions that empower the rare disease diagnosis and treatment industry and improve the level of rare disease gene therapy in China.